Optimization of a device for the storage, mixing and delivery of sterilized bone adhesive

用于灭菌储存、混合和控制递送生物粘合剂的beta原型装置的开发。** 2015年，加拿大报告了47,000例手腕骨折。据2010年估计，每年治疗手腕骨折的总费用为1.04亿美元。经皮骨折固定是一种改善手术效果的方法。**由主申请人Towler领导的工程师和临床医生联盟正在通过2016年获得的NSERC/CIHR CHRP资助开发专有的玻璃聚烯酸水泥（GPCs）。这些材料是可注射的，可以粘在骨头上，并且可以在骨折部位配制成抗菌和成骨。然而，与生物粘合剂同等重要的是“三合一”程序设备的开发和优化，它有助于：2.生物胶粘剂前体的储存；它们的均匀混合和3。它们由外科医生控制运送到骨折部位。总的来说，该解决方案（输送设备和生物粘合剂，从此称为“Kit”）将提供应用过程的标准化，减少与手术室中生物粘合剂处理不当相关的风险，这直接转化为加拿大医疗保健系统的成本节约结果。**该团队由Towler领导，由PDF Alhalawani协助，并与来自工程（Protodev Canada）和临床领域(dr。Zalzal和Safir)将在Towler的临时专利所涵盖的空间内修改alpha原型交付设备。该项目将生产出耐久性更好、复杂性更低、容量更大的测试版设备，这将扩展其功能。虽然该设备的预期用途是储存、混合并将生物粘合剂输送到手术部位，但所采取的步骤本质上不是临床，而是其方法中的基础工程，这可能导致该设备离开临床，用于诸如用于涂层、绝缘和密封应用的胶水和环氧树脂的输送等领域的开发

The development of a beta-prototype device for the sterilized storage, mixing and controlled delivery of a bioadhesive.**In 2015, there were 47,000 wrist fractures reported in Canada. A 2010 estimate for the total annual cost of treating wrist fractures was $104M. One method postulated for improving surgical outcomes in this space is percutaneous fracture fixation.**A consortia of engineers and clinicians, led by Principal Applicant Towler, are developing proprietary glass polyalkenoate cements (GPCs) through a NSERC/CIHR CHRP grant secured in 2016. These materials are injectable, adhesive to bone and can be formulated to be both antibacterial and osteogenic at the fracture site. However, of equal importance to the bioadhesive is the development and optimization of a '3-in-1' procedural device which facilitates: 1. the storage of the bioadhesive precursors, 2. their uniform mixing and 3. Their controlled delivery by surgeons to the fracture site. Collectively, the solution (the delivery device and the bioadhesive, henceforth known as the 'Kit'), will provide standardization of the application process, reducing risks associated with improper handling of the bioadhesive in operating rooms which directly translates to cost saving outcomes for the Canadian healthcare system.**The team, led by Towler, assisted by PDF Alhalawani and with collaborators from the engineering (Protodev Canada) and clinical fields (Drs. Zalzal and Safir), will amend an alpha prototype delivery device, within the space covered by Towler's provisional patent. The project will yield a beta device with improved durability, reduced complexity and increased capacity, which will expand its functionality. Although the intended use of**the device is to store, mix and deliver the bioadhesive to surgical sites, the steps being taken are not clinical in nature, but fundamental engineering in their approach which may result in a device that leaves the clinic for exploitation in fields such as the delivery of glues and epoxies for coating, insulation and sealing applications.**